| Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 |
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net loss | ||||||
-124,453 | -109,635 | -108,536 | -111,346 | 0 | 0 | 0 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
226 | 208 | 194 | 180 | 0 | 0 | 0 |
Share-based compensation expense | ||||||
16,147 | 4,451 | 4,219 | 3,978 | 0 | 0 | 0 |
Amortization of debt discount and issuance costs | ||||||
0 | 0 | 0 | - | - | - | - |
Amortization of operating lease right-of-use assets | ||||||
- | - | 0 | - | - | - | - |
Loss on disposal of furniture and equipment | ||||||
0 | 0 | 0 | - | - | - | - |
Unrealized foreign currency translation adjustment | ||||||
-74 | -261 | -670 | -262 | 0 | 0 | 0 |
Changes in operating assets and liabilities: | ||||||
Prepaid expenses and other current assets | ||||||
-5,379 | -3,190 | 2,272 | 7,462 | 0 | 0 | 0 |
Other assets | ||||||
0 | 0 | 0 | - | - | - | - |
Due to Roivant Sciences Ltd. | ||||||
- | - | -2,642 | - | - | - | 0 |
Accounts payable | ||||||
-1,308 | -3,067 | -2,283 | 1,092 | 0 | 0 | 0 |
Accrued expenses | ||||||
7,867 | -63 | -778 | 5,639 | 0 | 0 | 0 |
Net cash used in operating activities | ||||||
-94,502 | -111,660 | -110,780 | -109,036 | 0 | 0 | 0 |
Cash flows from investing activities: | ||||||
Purchases of furniture and equipment | ||||||
1,132 | 1,020 | 756 | 593 | 0 | 0 | 0 |
Net cash used in investing activities | ||||||
-1,132 | -1,020 | -756 | -593 | 0 | 0 | 0 |
Cash flows from financing activities: | ||||||
Proceeds from capital contributions from Roivant Sciences Ltd. | ||||||
292 | 1,577 | 23,261 | 41,631 | 0 | 0 | 0 |
Proceeds from exercise of stock options | ||||||
0 | 0 | 0 | - | - | - | - |
Debt financing costs paid | ||||||
0 | 0 | 0 | - | - | - | - |
Initial public offering costs paid | ||||||
- | - | - | - | - | 0 | 0 |
Net cash provided by financing activities | ||||||
131,964 | 179,683 | 170,509 | 188,631 | 0 | 0 | 0 |
Net change in cash, cash equivalents and restricted cash | ||||||
36,330 | 67,003 | 58,973 | 79,002 | 0 | 0 | 0 |
Non-cash financing activities: | ||||||
Furniture and equipment included in accounts payable and accrued expenses | ||||||
- | - | 0 | - | - | - | - |
Furniture and equipment included in due to Roivant Sciences Ltd. | ||||||
- | 0 | 0 | - | - | - | - |
Unpaid initial public offering costs included in accounts payable | ||||||
- | - | - | - | - | 0 | 0 |
Supplemental disclosure of cash paid: | ||||||
Interest | ||||||
0 | 0 | 0 | - | - | - | - |